Is there a role for immunotherapy in hepatocellular carcinoma?

A. Zerbini, M. Pilli, C. Ferrari, G. Missale

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Incidence of hepatocellular carcinoma has been rising in the last two decades because of the wide exposure to hepatitis C virus during 1960s and 1970s. Improvement in treatment has been achieved by local ablative therapies, however because of early recurrence and lack of effective chemotherapies, alternative treatments based on stimulation of the anti-tumour immune response could represent new strategies to control hepatocellular carcinoma spread and recurrence. Proof of principle of an effective immunotherapy has been achieved for other solid tumours such as melanoma and several results could be transferred to the immunotherapy of hepatocellular carcinoma. Specific tumour antigens have been identified in hepatocellular carcinoma, such as cancer testis antigens expressed in a large part of hepatocellular carcinomas and alpha-fetoprotein that has been already employed in clinical trials demonstrating immunogenicity without however significant clinical efficacy. Better results have been achieved by non-antigen-specific immunotherapies that demonstrated improvement in recurrence and recurrence-free survival in patients undergoing surgical resection for hepatocellular carcinoma. Passive immunotherapy and targeted therapies blocking tumour cell receptors or enzymatic pathways are already in the clinic for other malignancies and the near future will see these new treatments applied to hepatocellular carcinoma patients along with the development of efficacious active immunotherapies aimed at reducing disease recurrence and improving survival.

Original languageEnglish
Pages (from-to)221-225
Number of pages5
JournalDigestive and Liver Disease
Volume38
Issue number4
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Immunotherapy
Hepatocellular Carcinoma
Recurrence
Neoplasms
Therapeutics
Active Immunotherapy
Passive Immunization
Survival
Testicular Neoplasms
alpha-Fetoproteins
Neoplasm Antigens
Hepacivirus
Melanoma
Clinical Trials
Antigens
Drug Therapy
Incidence

Keywords

  • HBV
  • HCC
  • HCV
  • Immunotherapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Is there a role for immunotherapy in hepatocellular carcinoma? / Zerbini, A.; Pilli, M.; Ferrari, C.; Missale, G.

In: Digestive and Liver Disease, Vol. 38, No. 4, 04.2006, p. 221-225.

Research output: Contribution to journalArticle

Zerbini, A, Pilli, M, Ferrari, C & Missale, G 2006, 'Is there a role for immunotherapy in hepatocellular carcinoma?', Digestive and Liver Disease, vol. 38, no. 4, pp. 221-225. https://doi.org/10.1016/j.dld.2005.12.004
Zerbini, A. ; Pilli, M. ; Ferrari, C. ; Missale, G. / Is there a role for immunotherapy in hepatocellular carcinoma?. In: Digestive and Liver Disease. 2006 ; Vol. 38, No. 4. pp. 221-225.
@article{fb1785897bf24e4b8a4110b221859c45,
title = "Is there a role for immunotherapy in hepatocellular carcinoma?",
abstract = "Incidence of hepatocellular carcinoma has been rising in the last two decades because of the wide exposure to hepatitis C virus during 1960s and 1970s. Improvement in treatment has been achieved by local ablative therapies, however because of early recurrence and lack of effective chemotherapies, alternative treatments based on stimulation of the anti-tumour immune response could represent new strategies to control hepatocellular carcinoma spread and recurrence. Proof of principle of an effective immunotherapy has been achieved for other solid tumours such as melanoma and several results could be transferred to the immunotherapy of hepatocellular carcinoma. Specific tumour antigens have been identified in hepatocellular carcinoma, such as cancer testis antigens expressed in a large part of hepatocellular carcinomas and alpha-fetoprotein that has been already employed in clinical trials demonstrating immunogenicity without however significant clinical efficacy. Better results have been achieved by non-antigen-specific immunotherapies that demonstrated improvement in recurrence and recurrence-free survival in patients undergoing surgical resection for hepatocellular carcinoma. Passive immunotherapy and targeted therapies blocking tumour cell receptors or enzymatic pathways are already in the clinic for other malignancies and the near future will see these new treatments applied to hepatocellular carcinoma patients along with the development of efficacious active immunotherapies aimed at reducing disease recurrence and improving survival.",
keywords = "HBV, HCC, HCV, Immunotherapy",
author = "A. Zerbini and M. Pilli and C. Ferrari and G. Missale",
year = "2006",
month = "4",
doi = "10.1016/j.dld.2005.12.004",
language = "English",
volume = "38",
pages = "221--225",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "4",

}

TY - JOUR

T1 - Is there a role for immunotherapy in hepatocellular carcinoma?

AU - Zerbini, A.

AU - Pilli, M.

AU - Ferrari, C.

AU - Missale, G.

PY - 2006/4

Y1 - 2006/4

N2 - Incidence of hepatocellular carcinoma has been rising in the last two decades because of the wide exposure to hepatitis C virus during 1960s and 1970s. Improvement in treatment has been achieved by local ablative therapies, however because of early recurrence and lack of effective chemotherapies, alternative treatments based on stimulation of the anti-tumour immune response could represent new strategies to control hepatocellular carcinoma spread and recurrence. Proof of principle of an effective immunotherapy has been achieved for other solid tumours such as melanoma and several results could be transferred to the immunotherapy of hepatocellular carcinoma. Specific tumour antigens have been identified in hepatocellular carcinoma, such as cancer testis antigens expressed in a large part of hepatocellular carcinomas and alpha-fetoprotein that has been already employed in clinical trials demonstrating immunogenicity without however significant clinical efficacy. Better results have been achieved by non-antigen-specific immunotherapies that demonstrated improvement in recurrence and recurrence-free survival in patients undergoing surgical resection for hepatocellular carcinoma. Passive immunotherapy and targeted therapies blocking tumour cell receptors or enzymatic pathways are already in the clinic for other malignancies and the near future will see these new treatments applied to hepatocellular carcinoma patients along with the development of efficacious active immunotherapies aimed at reducing disease recurrence and improving survival.

AB - Incidence of hepatocellular carcinoma has been rising in the last two decades because of the wide exposure to hepatitis C virus during 1960s and 1970s. Improvement in treatment has been achieved by local ablative therapies, however because of early recurrence and lack of effective chemotherapies, alternative treatments based on stimulation of the anti-tumour immune response could represent new strategies to control hepatocellular carcinoma spread and recurrence. Proof of principle of an effective immunotherapy has been achieved for other solid tumours such as melanoma and several results could be transferred to the immunotherapy of hepatocellular carcinoma. Specific tumour antigens have been identified in hepatocellular carcinoma, such as cancer testis antigens expressed in a large part of hepatocellular carcinomas and alpha-fetoprotein that has been already employed in clinical trials demonstrating immunogenicity without however significant clinical efficacy. Better results have been achieved by non-antigen-specific immunotherapies that demonstrated improvement in recurrence and recurrence-free survival in patients undergoing surgical resection for hepatocellular carcinoma. Passive immunotherapy and targeted therapies blocking tumour cell receptors or enzymatic pathways are already in the clinic for other malignancies and the near future will see these new treatments applied to hepatocellular carcinoma patients along with the development of efficacious active immunotherapies aimed at reducing disease recurrence and improving survival.

KW - HBV

KW - HCC

KW - HCV

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=33748515904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748515904&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2005.12.004

DO - 10.1016/j.dld.2005.12.004

M3 - Article

C2 - 16461021

AN - SCOPUS:33748515904

VL - 38

SP - 221

EP - 225

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 4

ER -